Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
Status:
Terminated
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safest dose of XL999 and how well subjects with
Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple
kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell
growth, formation of new blood vessels (angiogenesis), and metastasis.